semaj83/ctmatch_classification huggingface dataset:
Patient description: The patient is a 3-day-old female infant with jaundice that started one day ago. She was born at 34w of gestation and kept in an incubator due to her gestational age. Vital signs were reported as: axillary temperature: 36.3°C, heart rate: 154 beats/min, respiratory rate: 37 breaths/min, and blood pressure: 65/33 mm Hg. Her weight is 2.1 kg, length is 45 cm, and head circumference 32 cm. She presents with yellow sclera and icteric body. Her liver and spleen are normal to palpation. Laboratory results are as follows: Serum total bilirubin: 21.02 mg/dL Direct bilirubin of 2.04 mg/dL AST: 37 U/L ALT: 20 U/L GGT: 745 U/L Alkaline phosphatase: 531 U/L Creatinine: 0.3 mg/dL Urea: 29 mg/dL Na: 147 mEq/L K: 4.5 mEq/L CRP: 3 mg/L Complete blood cell count within the normal range. She is diagnosed with neonatal jaundice that may require phototherapy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-70.0,  Metabolic Syndrome x Glucose Metabolism Disorders Dyslipidemias Obesity Aged between 18 and 70 years old Caucasian Insulin resistance (based on HOMA single-value) BMI between 25 and 50 kg/m² Metabolic syndrome: presence of at least 3 of the following Hypertension (blood pressure ≥ 130/85 mm Hg or antihypertensive treatment) Hypertriglyceridemia (triglyceridemia ≥ 150mg/dl) Low HDL-cholesterol (HDL-cholesterol < 40mg/dl for males, 50mg/dl for females) Visceral obesity (waist circumference > 102 cm for males, 88cm for females) Fasting hyperglycemia (fasting glycemia ≥ 110mg/dl)  Acute or chronic progressive or chronic unstabilized diseases Alcohol consumption (more than 2 glasses per day) Previous bariatric surgery Surgery in the 3 months prior the study or surgery planned in the next 6 months Pregnancy or pregnancy planned in the next 6 months More than 30 minutes of sports 3 times per week Consumption of dietary supplement (omega-3 fatty acids, probiotics, prebiotics, plant stanols/sterols) in the month prior the study Inflammatory bowel disease or irritable bowel syndrome Diabetic gastrointestinal autonomic neuropathy (such as gastroparesis or reduced gastrointestinal motility) Consumption of more than 30g of dietary fibers per day
Patient description: The patient is a 3-day-old female infant with jaundice that started one day ago. She was born at 34w of gestation and kept in an incubator due to her gestational age. Vital signs were reported as: axillary temperature: 36.3°C, heart rate: 154 beats/min, respiratory rate: 37 breaths/min, and blood pressure: 65/33 mm Hg. Her weight is 2.1 kg, length is 45 cm, and head circumference 32 cm. She presents with yellow sclera and icteric body. Her liver and spleen are normal to palpation. Laboratory results are as follows: Serum total bilirubin: 21.02 mg/dL Direct bilirubin of 2.04 mg/dL AST: 37 U/L ALT: 20 U/L GGT: 745 U/L Alkaline phosphatase: 531 U/L Creatinine: 0.3 mg/dL Urea: 29 mg/dL Na: 147 mEq/L K: 4.5 mEq/L CRP: 3 mg/L Complete blood cell count within the normal range. She is diagnosed with neonatal jaundice that may require phototherapy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-35.0,  Healthy Volunteers Both genders, between the ages of 18 and 35 years old Willing and able to provide informed consent Body Mass Index between 18.5 and 24.9 (normal) Normal blood work, according to following Leucocytes >3,000; Platelets >100,000; Hemoglobin >10.0 g/dL; AST, ALT and bilirubin < 2 times UNL; Creatinine < 2 times UNL Normal ECG and chest x-rays, at the discretion of the cardiologist and radiologist, respectively Negative urine pregnancy test (Women in childbearing age, sexually active) Willing to return for follow-up as required by the study  History of psychiatric condition Pregnant or lactating women Clinically significant abnormalities on the ECG Presence of medical or social conditions that, in opinion of the investigator, may prevent the proper participation of the volunteer subject in the study or in the assessment of its outcomes Presence of an active systemic infection Subjects receiving medical treatment for any medical condition, either acute or chronic Recent (< 6 months) major surgery Recent (< 1 year) alcohol abuse or illegal drug use
Patient description: The patient is a 3-day-old female infant with jaundice that started one day ago. She was born at 34w of gestation and kept in an incubator due to her gestational age. Vital signs were reported as: axillary temperature: 36.3°C, heart rate: 154 beats/min, respiratory rate: 37 breaths/min, and blood pressure: 65/33 mm Hg. Her weight is 2.1 kg, length is 45 cm, and head circumference 32 cm. She presents with yellow sclera and icteric body. Her liver and spleen are normal to palpation. Laboratory results are as follows: Serum total bilirubin: 21.02 mg/dL Direct bilirubin of 2.04 mg/dL AST: 37 U/L ALT: 20 U/L GGT: 745 U/L Alkaline phosphatase: 531 U/L Creatinine: 0.3 mg/dL Urea: 29 mg/dL Na: 147 mEq/L K: 4.5 mEq/L CRP: 3 mg/L Complete blood cell count within the normal range. She is diagnosed with neonatal jaundice that may require phototherapy.

Clinical trial eligibility criteria: eligible ages (years): 0.5-999.0,  Malaria Male or female, aged over 6 months old Acute severe P. falciparum malaria or another indication to treat with IV artesunate. Defined as one or more of the following, occurring in the absence of an identified alternative cause, and in the presence of P. falciparum asexual parasitaemia Prostration OR obtundation BCS<3 (preverbal children) or GCS<11 (adults) Convulsion in last 24 hours Suspected acidosis, manifesting as acidotic breathing Respiratory distress manifesting clinically (nasal flaring/indrawing) or oxygen saturation <92% or respiratory rate >30/min History of anuria Jaundice and/or hemoglobinuria Hemoglobin <7 g/dl or hematocrit <20%  History of 2 or more doses of parenteral antimalarial treatment in the previous 24 hours History of allergy or known contraindication to artemisinins
Patient description: The patient is a 3-day-old female infant with jaundice that started one day ago. She was born at 34w of gestation and kept in an incubator due to her gestational age. Vital signs were reported as: axillary temperature: 36.3°C, heart rate: 154 beats/min, respiratory rate: 37 breaths/min, and blood pressure: 65/33 mm Hg. Her weight is 2.1 kg, length is 45 cm, and head circumference 32 cm. She presents with yellow sclera and icteric body. Her liver and spleen are normal to palpation. Laboratory results are as follows: Serum total bilirubin: 21.02 mg/dL Direct bilirubin of 2.04 mg/dL AST: 37 U/L ALT: 20 U/L GGT: 745 U/L Alkaline phosphatase: 531 U/L Creatinine: 0.3 mg/dL Urea: 29 mg/dL Na: 147 mEq/L K: 4.5 mEq/L CRP: 3 mg/L Complete blood cell count within the normal range. She is diagnosed with neonatal jaundice that may require phototherapy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-55.0,  Healthy Healthy male or female subjects Preferably non-smokers or smoke less than 10 cigarettes per day Body mass index within 18 to 25 kg/m2 Normal vital signs (after 10 minutes rest): systolic blood pressure 100 mmHg, diastolic blood pressure 60 mmHg, pulse rate 60 bpm  Personal / family history of allergy or hypersensitivity or contraindication to pramipexole or allied drugs Pregnant or lactating women Any major illness in the past 90 days or clinically significant ongoing chronic medical illness Any clinically significant abnormal values of liver function test (ALT, alkaline phosphatase, total bilirubin >= 1.5 upper limit normal), renal function test (serum creatinine > 1.4 mg/dL), etc Positive Hepatitis B surface antigen (HbsAg), anti-HCV, or anti-HIV Clinically significant hematology abnormalities Clinically significant ECG abnormalities Any surgical or medical condition (present or history) which might significantly alter the pharmacokinetics of the study drug History of anaphylaxis or angioedema History of drug or alcohol abuse within 12 months prior to screening
Patient description: The patient is a 3-day-old female infant with jaundice that started one day ago. She was born at 34w of gestation and kept in an incubator due to her gestational age. Vital signs were reported as: axillary temperature: 36.3°C, heart rate: 154 beats/min, respiratory rate: 37 breaths/min, and blood pressure: 65/33 mm Hg. Her weight is 2.1 kg, length is 45 cm, and head circumference 32 cm. She presents with yellow sclera and icteric body. Her liver and spleen are normal to palpation. Laboratory results are as follows: Serum total bilirubin: 21.02 mg/dL Direct bilirubin of 2.04 mg/dL AST: 37 U/L ALT: 20 U/L GGT: 745 U/L Alkaline phosphatase: 531 U/L Creatinine: 0.3 mg/dL Urea: 29 mg/dL Na: 147 mEq/L K: 4.5 mEq/L CRP: 3 mg/L Complete blood cell count within the normal range. She is diagnosed with neonatal jaundice that may require phototherapy.

Clinical trial eligibility criteria: eligible ages (years): 0.25-999.0,  Tropical Infectious Diseases Children between ages >3 months and < 15 years old OR adults of 15 years and above 2. AND willing and able to provide written informed consent (parent's or guardian's consent for minors). In case of very sick adults not able to give consent, sampling will be done and ICF will be asked upon his/her recovery or from his/her representative in case of death. 3. AND presenting with one of the following: Recorded temperature of > 38.0°C or temperature < 35.5°C (tympanic). OR episode of fever within 48 hours prior to admission OR signs of severe clinical illness including one or more of the following Respiratory distress Prostration Altered consciousness Convulsions (one or more episodes) Clinical jaundice Signs of shock Severe malnutrition with severe anemia (hemoglobin < 5 g/dl) 4. AND Having one of the following clinically suspected infections Severe malaria Invasive bacterial infection (including pneumonia, arthritis, peritonitis, meningitis or complicated urinary tract infection, typhoid fever)  • Fever episode for more than 7 days or no informed consent was given
Patient description: The patient is a 3-day-old female infant with jaundice that started one day ago. She was born at 34w of gestation and kept in an incubator due to her gestational age. Vital signs were reported as: axillary temperature: 36.3°C, heart rate: 154 beats/min, respiratory rate: 37 breaths/min, and blood pressure: 65/33 mm Hg. Her weight is 2.1 kg, length is 45 cm, and head circumference 32 cm. She presents with yellow sclera and icteric body. Her liver and spleen are normal to palpation. Laboratory results are as follows: Serum total bilirubin: 21.02 mg/dL Direct bilirubin of 2.04 mg/dL AST: 37 U/L ALT: 20 U/L GGT: 745 U/L Alkaline phosphatase: 531 U/L Creatinine: 0.3 mg/dL Urea: 29 mg/dL Na: 147 mEq/L K: 4.5 mEq/L CRP: 3 mg/L Complete blood cell count within the normal range. She is diagnosed with neonatal jaundice that may require phototherapy.

Clinical trial eligibility criteria: eligible ages (years): 0.0-0.082,  Prematurity, Mechanical Ventilation Infants born at less than 37 weeks' gestation, required endotracheal intubation and positive pressure ventilation, and are considered ready for extubation by the clinical team. Infants will be enrolled after written informed parental consent is obtained  Suspected upper airway obstruction, congenital airway malformations, or major cardiopulmonary malformations
Patient description: The patient is a 3-day-old female infant with jaundice that started one day ago. She was born at 34w of gestation and kept in an incubator due to her gestational age. Vital signs were reported as: axillary temperature: 36.3°C, heart rate: 154 beats/min, respiratory rate: 37 breaths/min, and blood pressure: 65/33 mm Hg. Her weight is 2.1 kg, length is 45 cm, and head circumference 32 cm. She presents with yellow sclera and icteric body. Her liver and spleen are normal to palpation. Laboratory results are as follows: Serum total bilirubin: 21.02 mg/dL Direct bilirubin of 2.04 mg/dL AST: 37 U/L ALT: 20 U/L GGT: 745 U/L Alkaline phosphatase: 531 U/L Creatinine: 0.3 mg/dL Urea: 29 mg/dL Na: 147 mEq/L K: 4.5 mEq/L CRP: 3 mg/L Complete blood cell count within the normal range. She is diagnosed with neonatal jaundice that may require phototherapy.

Clinical trial eligibility criteria: eligible ages (years): 0.0-0.333,  Laryngomalacia Acid Reflux Stridor age 0 months old stridor and flexible laryngoscopy demonstrating laryngomalacia airway symptom score over 4 only has physiologic GER (I-GERQ < 16)  requiring surgery for LGM other airway dz seen on flexible laryngoscopy history of or already on PPI therapy minimal/mild airway symptoms (airway score < 4) pathologic GERD (I-GERQ greater than 16) These pts cannot be randomized because this is the standard score in Pediatric GI literature strongly indicating anti-reflux meds premature birth (< 36 weeks)
Patient description: The patient is a 3-day-old female infant with jaundice that started one day ago. She was born at 34w of gestation and kept in an incubator due to her gestational age. Vital signs were reported as: axillary temperature: 36.3°C, heart rate: 154 beats/min, respiratory rate: 37 breaths/min, and blood pressure: 65/33 mm Hg. Her weight is 2.1 kg, length is 45 cm, and head circumference 32 cm. She presents with yellow sclera and icteric body. Her liver and spleen are normal to palpation. Laboratory results are as follows: Serum total bilirubin: 21.02 mg/dL Direct bilirubin of 2.04 mg/dL AST: 37 U/L ALT: 20 U/L GGT: 745 U/L Alkaline phosphatase: 531 U/L Creatinine: 0.3 mg/dL Urea: 29 mg/dL Na: 147 mEq/L K: 4.5 mEq/L CRP: 3 mg/L Complete blood cell count within the normal range. She is diagnosed with neonatal jaundice that may require phototherapy.

Clinical trial eligibility criteria: eligible ages (years): 0.167-999.0,  Meulengracht Syndrome Hyperbilirubinemia Unconjugated Benign Bilirubinemia Informed consent will be obtained from the patient or the parents before any study related procedures Patients of both genders older than 2 months The patient has a diagnosis of Gilbert disease or a high-grade suspicion for Gilbert disease High-grade suspicion present, if one or more are valid: 1 Positive family anamnesis for Gilbert disease 2 Hyperbilirubinemia 3 Abdominal pain 4 Irritable bowel syndrome 5 Familial nonhemolytic jaundice  No Informed consent from the patient or the parents before any study related procedures Patients of both gender younger than 2 months No diagnosis of Gilbert disease or no valid for profound suspicion of Gilbert disease
Patient description: The patient is a 3-day-old female infant with jaundice that started one day ago. She was born at 34w of gestation and kept in an incubator due to her gestational age. Vital signs were reported as: axillary temperature: 36.3°C, heart rate: 154 beats/min, respiratory rate: 37 breaths/min, and blood pressure: 65/33 mm Hg. Her weight is 2.1 kg, length is 45 cm, and head circumference 32 cm. She presents with yellow sclera and icteric body. Her liver and spleen are normal to palpation. Laboratory results are as follows: Serum total bilirubin: 21.02 mg/dL Direct bilirubin of 2.04 mg/dL AST: 37 U/L ALT: 20 U/L GGT: 745 U/L Alkaline phosphatase: 531 U/L Creatinine: 0.3 mg/dL Urea: 29 mg/dL Na: 147 mEq/L K: 4.5 mEq/L CRP: 3 mg/L Complete blood cell count within the normal range. She is diagnosed with neonatal jaundice that may require phototherapy.

Clinical trial eligibility criteria: eligible ages (years): 0.0-0.058,  Kernicterus Newborn infant receiving treatment for neonatal jaundice  Non-viable premature infants Severe congenital defects Postnatal age greater than 21 days
Patient description: The patient is a 3-day-old female infant with jaundice that started one day ago. She was born at 34w of gestation and kept in an incubator due to her gestational age. Vital signs were reported as: axillary temperature: 36.3°C, heart rate: 154 beats/min, respiratory rate: 37 breaths/min, and blood pressure: 65/33 mm Hg. Her weight is 2.1 kg, length is 45 cm, and head circumference 32 cm. She presents with yellow sclera and icteric body. Her liver and spleen are normal to palpation. Laboratory results are as follows: Serum total bilirubin: 21.02 mg/dL Direct bilirubin of 2.04 mg/dL AST: 37 U/L ALT: 20 U/L GGT: 745 U/L Alkaline phosphatase: 531 U/L Creatinine: 0.3 mg/dL Urea: 29 mg/dL Na: 147 mEq/L K: 4.5 mEq/L CRP: 3 mg/L Complete blood cell count within the normal range. She is diagnosed with neonatal jaundice that may require phototherapy.

Clinical trial eligibility criteria: eligible ages (years): 20.0-60.0,  Healthy Volunteers Male body weight must be over 50 ㎏, Female body weight must be over 45㎏ Temperature less than 37.5 Celsius Systolic blood pressure greater than 90 and less than 180 ㎜Hg Diastolic blood pressure less than 100 ㎜Hg Heart rate between 50 to 100 beats per minute No abnormality in CBC(complete blood count) and PT/aPTT(prothrombin time /activated Partial Thromboplastin Time)Test ALT(ALanine Transaminase) Less than 65IU/L No history of bleeding and bleeding diathesis  Drinking more than 3 alcoholic drinks per week Under the 12.5g/dl hemoglobin (38% packed cell volume) Positive tests for blood borne pathogens (HBV, HCV(Hepatitis C Virus), HIV, HTLV(human T lymphotropic virus)-I,II, syphilis, CMV(Cyto-Megalo-Virus), EBV(Epstein-Barr Virus)) Person who falls short of health standards, such as a patient with an infectious disease or a patient who take medication, who is prescribed by Ordinance of the Ministry of Health and Welfare as unfit to donate blood Donor taking prescription medications other than those deemed allowable by the investigator Aspirin within prior 3 days Ticlopidine within prior 2 weeks Isotretinoin, Finasteride within prior 1 month Dutasteride within prior 6 months Hepatitis B immune globulin(HBIG), Placental Extract within prior 1 year
Patient description: The patient is a 3-day-old female infant with jaundice that started one day ago. She was born at 34w of gestation and kept in an incubator due to her gestational age. Vital signs were reported as: axillary temperature: 36.3°C, heart rate: 154 beats/min, respiratory rate: 37 breaths/min, and blood pressure: 65/33 mm Hg. Her weight is 2.1 kg, length is 45 cm, and head circumference 32 cm. She presents with yellow sclera and icteric body. Her liver and spleen are normal to palpation. Laboratory results are as follows: Serum total bilirubin: 21.02 mg/dL Direct bilirubin of 2.04 mg/dL AST: 37 U/L ALT: 20 U/L GGT: 745 U/L Alkaline phosphatase: 531 U/L Creatinine: 0.3 mg/dL Urea: 29 mg/dL Na: 147 mEq/L K: 4.5 mEq/L CRP: 3 mg/L Complete blood cell count within the normal range. She is diagnosed with neonatal jaundice that may require phototherapy.

Clinical trial eligibility criteria: eligible ages (years): 0.5-4.917,  Malaria Age between 6 and 59 months Weight ≥ 5 Kg Slide-confirmed infection with Plasmodium falciparum only (no mixed infections) Asexual parasite density between 2000 and 200000/µl of blood Measured axillary temperature ≥ 37.5°C Ability to swallow oral medication High probability of respecting the follow-up visits (residence within 1 hour walking distance from the OPD, no upcoming travel plans, etc.) Informed consent from a parent or caretaker aged at least 18 years  • General danger signs according to the WHO definition (Appendix 5.1.1) Signs of severe/complicated malaria according to the WHO definition (Appendix 5.1.2) Severe anaemia (haemoglobin < 5 g/dL) Known history of hypersensitivity to any of the study drugs Severe acute malnutrition (as defined by a weight-for-height below -3 Z-score and/or symmetrical oedemas involving at least the feet) Concomitant febrile illness due to causes other than malaria with the potential to confound study outcome (measles, acute lower tract respiratory infection, otitis media, tonsillitis, abscesses, severe diarrhoea with dehydration) Having received already a full course of the treatment (or one of the treatments) under study in the previous 28 days (as indicated by the parent/caretaker). Note that previous incomplete anti-malarial intake of treatments under study, or previous intake of anti-malarials not under study, are not  but details of any such intake should be recorded carefully History of hypersensitivity reactions or contra-indications to any medicines being tested
Patient description: The patient is a 3-day-old female infant with jaundice that started one day ago. She was born at 34w of gestation and kept in an incubator due to her gestational age. Vital signs were reported as: axillary temperature: 36.3°C, heart rate: 154 beats/min, respiratory rate: 37 breaths/min, and blood pressure: 65/33 mm Hg. Her weight is 2.1 kg, length is 45 cm, and head circumference 32 cm. She presents with yellow sclera and icteric body. Her liver and spleen are normal to palpation. Laboratory results are as follows: Serum total bilirubin: 21.02 mg/dL Direct bilirubin of 2.04 mg/dL AST: 37 U/L ALT: 20 U/L GGT: 745 U/L Alkaline phosphatase: 531 U/L Creatinine: 0.3 mg/dL Urea: 29 mg/dL Na: 147 mEq/L K: 4.5 mEq/L CRP: 3 mg/L Complete blood cell count within the normal range. She is diagnosed with neonatal jaundice that may require phototherapy.

Clinical trial eligibility criteria: eligible ages (years): 0.0-60.0,  Severe Aplastic Anemia Diagnosis of AA confirmed by bone marrow aspirate and biopsy, myelodysplastic syndrome and paroxysmal nocturnal hemoglobinuria were excluded. To confirm severe AA, the patient must fulfill at least two of the i) ANC<0.5×109/L,ii)PLT<20×109/L and iii) Ret<20×109/L ,in addition, ANC<0.5×109/L must be included. 2. Under 60 years old, male or female. 3. No HLA matched siblings. 4. No previous ATG treatment history. 5. Performance status score no more than 2 (ECOG criteria). 6．Adequate organ function as defined by the following criteria:ALT, AST and total serum bilirubin <2×ULN (upper limit of normal) Serum creatinine and BUN <1.25×ULN. 7. Adequate cardiac function without acute myocardial infarction, arrhythmia or atrioventricular block, heart failure, active rheumatic heart disease and cardiac dilatation. 8．Signed and dated informed consent document indicating that the patient (or legally acceptable representative) has been informed of all pertinent aspects of the trial prior to enrollment. 9. Willingness and ability to comly with scheduled visits, treatment plans, laboratory tests, and other study procedures  Presence of any condition inappropriate for HSCT. 2. Presence of any fatal disease, including respiratory failure, heart failure, liver or kidney function failure et al. 3．Severely allergic to biologic products. 4．Pregnancy or breastfeeding. 5．Current treatment on another clinical trail. 6．Any other condition the investigator judged the patient inappropriate for entry into this study
Patient description: The patient is a 3-day-old female infant with jaundice that started one day ago. She was born at 34w of gestation and kept in an incubator due to her gestational age. Vital signs were reported as: axillary temperature: 36.3°C, heart rate: 154 beats/min, respiratory rate: 37 breaths/min, and blood pressure: 65/33 mm Hg. Her weight is 2.1 kg, length is 45 cm, and head circumference 32 cm. She presents with yellow sclera and icteric body. Her liver and spleen are normal to palpation. Laboratory results are as follows: Serum total bilirubin: 21.02 mg/dL Direct bilirubin of 2.04 mg/dL AST: 37 U/L ALT: 20 U/L GGT: 745 U/L Alkaline phosphatase: 531 U/L Creatinine: 0.3 mg/dL Urea: 29 mg/dL Na: 147 mEq/L K: 4.5 mEq/L CRP: 3 mg/L Complete blood cell count within the normal range. She is diagnosed with neonatal jaundice that may require phototherapy.

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  Pregnancy,Neoplastic Complications Any pregnant woman diagnosed with cancer within 6 weeks before her last menstrual period or 6 months after her end of pregnancy either by delivery or miscarriage  Women diagnosed with cancer more than 6 months after the end of a pregnancy